Protocol Ledger

NCT04126031 · Phase II · TERMINATED

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

Interventional Phase II clinical trial protocol NCT04126031 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-14 Enrollment: 48 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04126031
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04126031
Protocol FieldVerified Registry Value
NCT IdentifierNCT04126031
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment48 participants (ACTUAL)
Registered Start Date2020-01-14
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04126031
Hospital Research SiteLocationSite Profile
Duke University Medical CenterDurham, NCOpen Hospital Dossier ->
Huntsman Cancer Institute at University of UtahSalt Lake City, UTOpen Hospital Dossier ->
Primary Children's HospitalSalt Lake City, UTOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI